Drugs / Genetically modified T cells # 1138
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01645293 | — | mycosis fungoides variant, primary cutaneous CD30+ T-cell lymphoproliferative disease | University of Cologne | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Genetically modified T cells # 1138 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01645293 ↗ |
| Modality | Cell therapy | “Genetically modified T cells # 1138” NCT01645293 ↗ |